You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 17, 2024

Details for Patent: 11,124,526


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,124,526 protect, and when does it expire?

Patent 11,124,526 protects EXBLIFEP and is included in one NDA.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 11,124,526
Title:Crystalline beta-lactamase inhibitor
Abstract:A crystalline compound of formula (I):
Inventor(s):Lamonica Alessandro, Forzatti Marco, Biondi Stefano
Assignee:Allecra Therapeutics SAS
Application Number:US16177406
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 11,124,526

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allecra Theraps EXBLIFEP cefepime hydrochloride; enmetazobactam POWDER;INTRAVENOUS 216165-001 Feb 22, 2024 DISCN Yes No ⤷  Sign Up ⤷  Sign Up USE OF SPECIFIED POLYMORPHS OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,124,526

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014345507 ⤷  Sign Up
Canada 2929199 ⤷  Sign Up
Chile 2016001097 ⤷  Sign Up
China 105873935 ⤷  Sign Up
Eurasian Patent Organization 031348 ⤷  Sign Up
Eurasian Patent Organization 201690963 ⤷  Sign Up
European Patent Office 3066103 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.